ClinicalTrials.gov
ClinicalTrials.gov Menu

Blood Component Collection From Patients With Rheumatic or Kidney Disease and Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00031174
Recruitment Status : Recruiting
First Posted : February 27, 2002
Last Update Posted : August 9, 2018
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) )

Brief Summary:

This study will collect white blood cells or plasma (the liquid part of the blood), or both, from healthy volunteers and from patients with rheumatic or kidney disorders for research purposes. Rheumatic disorders involve abnormalities of the immune system, the body s defense against disease. The immune system consists of white blood cells such as lymphocytes and monocytes, which produce substances such as antibodies and cytokines. White cells and plasma will be collected through a procedure called apheresis (described below).

Healthy volunteers and patients with confirmed or suspected rheumatic or kidney disease who are 18 years of age or older may be eligible for this study. Patients must be participating in a current protocol of the National Institute of Arthritis and Musculoskeletal and Skin Diseases or the National Institute of Digestive, Diabetes and Kidney Diseases. All candidates will be screened with a history, physical examination, and blood tests for hepatitis B and C and HIV infection. Women of childbearing age will be tested for pregnancy. Routine blood tests will be done in all volunteers, and in patients where needed. Pregnant women and people who test positive for hepatitis or HIV may not participate.

Participants will undergo apheresis to collect lymphocytes, monocytes, or plasma from the blood. For this procedure, a needle is placed in a vein in the arm. Blood flows from the vein through a tube (catheter) into a machine that spins the blood, separating it into its components. The required cells or plasma are extracted, and the rest of the blood, including the red cells and platelets, is returned to the body through the same needle or through a second needle placed in the other arm.

Cells collected from volunteers will be used in studies comparing the number and function of similar cells from patients with rheumatic diseases, focusing on the differences in number and function of the cells in health and disease. Components collected from patients will be used only for studies described in the protocol in which they are currently enrolled.


Condition or disease
Rheumatic Diseases Healthy Volunteers

Detailed Description:
Blood components will be collected using apheresis from normal volunteers and patients with rheumatic or kidney diseases. Mononuclear cells and plasma will be used by various investigators for research studies.

Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Collection Of Blood Components Using Apheresis From Patients With Rheumatic or Kidney Diseases and Healthy Volunteers
Study Start Date : February 25, 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases




Primary Outcome Measures :
  1. PBMC and Mononuclear cell study [ Time Frame: One Year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA - Subjects with Rheumatic Diseases:

Patients with a diagnosed or suspected rheumatic or kidney disease, who are actively involved in a NIAMS or NIDDK protocol (have a current, signed consent form)

Ability to give informed consent

Age greater than or equal to 18 years

EXCLUSION CRITERIA - Subjects with Rheumatic Diseases:

History of allergy to acid-citrate-dextrose (ACD) anticoagulant

History of bleeding diatheses

Hemoglobin less than 9.0 g/dL

Platelet count less than 50,000/mm(3)

Pregnancy

Inadequate peripheral venous access

Active hepatitis B, C and/or HIV infection

Symptomatic coronary artery or valvular heart disease

Any concomitant illness that in the opinion of the investigators will substantially increase the risk of apheresis.

INCLUSION CRITERIA - Healthy Volunteers:

Subjects shall meet all donor eligibility criteria for autologous blood donation recommended or required by the Standards of the American Association of Blood Banks (1) and the Code of Federal Regulations of the Food and Drug Administration (2), with the exception of the travel exclusions related to malaria exposure and hypothetical exposure to the agent of variant Creutzfeldt-Jacob disease.

Ability to give informed consent

Age greater than or equal to 18 years

EXCLUSION CRITERIA - Healthy Volunteers:

History of autoimmune or chronic rheumatic disease within the last 5 years, with the exception of osteoarthritis

Active hepatitis B, C, and/or HIV infection

History of allergy to acid-citrate (ACD) anticoagulant

History of coagulopathies and bleeding diatheses

Symptomatic coronary artery disease or valvular heart disease

Hemoglobin less than 12.0 g/dL

Platelet count less than 100,000/cubic mm

Pregnancy

Inadequate peripheral venous access

Any concomitant illness that in the opinion of the investigators will substantially increase the risk of apheresis or make the volunteer ineligible for study controls are needed for (eg: active infection, allergies, etc.)


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00031174


Contacts
Contact: Sarfaraz A Hasni, M.D. (301) 451-1599 hasnisa@mail.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov   
Sponsors and Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Investigators
Principal Investigator: Sarfaraz A Hasni, M.D. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Additional Information:
Responsible Party: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ClinicalTrials.gov Identifier: NCT00031174     History of Changes
Other Study ID Numbers: 020131
02-AR-0131
First Posted: February 27, 2002    Key Record Dates
Last Update Posted: August 9, 2018
Last Verified: February 21, 2018

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ):
Apheresis
Healthy Volunteer
Rheumatoid Disease
Rheumatic Disease
Lupus
Rheumatoid Arthritis
Myositis
HV
Normal Control

Additional relevant MeSH terms:
Kidney Diseases
Rheumatic Diseases
Collagen Diseases
Urologic Diseases
Musculoskeletal Diseases
Connective Tissue Diseases